**Name of Journal: *World Journal of Gastroenterology***

**ESPS Manuscript NO: 32388**

**Manuscript Type: REVIEW**

**Brain changes in patients with Crohn’s disease detected by functional magnetic resonance imaging and spectroscopy**

Lv K *et al*. fMRI and MRS in CD

Kun Lv, Yi-hong Fan, Li Xu, Mao-sheng Xu

**Kun Lv,** The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang Province, China

**Kun Lv,** **Mao-sheng Xu,** Department of Radiology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, Zhejiang Province, China

**Yi-hong Fan,** Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, Zhejiang Province, China

**Li Xu,** Department of Coloproctology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, Zhejiang Province, China

**Authors’ contribution:** All authors contributed to this paper; Xu MS and Fan YH designed the outline for the review; Lv K wrote the review; Xu L offered assistance for grammatical revision of the paper; Xu MS and Lv K revised and edited the final version.

**Supported by** the National Natural Science Foundation of China, No. 81473506; the Natural Science Foundation of Zhejiang Province, No. LY17H290009; and the Ministry of construction, Zhejiang Province, No. WKJ-ZJ-1531.

**Conflict-of-interest statement:** No potential conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Mao-sheng Xu, MD, PhD, Chief,** Department of Radiology, The First Affiliated Hospital of Zhejiang Chinese Medical University, 54 Youdian Road, ShangCheng District, Hangzhou 310006, Zhejiang Province, China. xums166@126.com

**Telephone:** +86-571-87070272

**Fax:** +86-571-87077785

**Received:** January 5, 2017

**Peer-review started:** January 6, 2017

**First decision:** January 19, 2017

**Revised:** February 6, 2017

**Accepted:** March 30, 2017

**Article in press:**

**Published online:**

**Abstract**

Crohn’s disease (CD) is a chronic, non-specific granulomatous inflammation which commonly affects the small intestine and is a phenotype of inflammatory bowel disease (IBD). CD is prone to relapse, and its occurrence displays a persistent increase in developing countries. However, the pathogenesis of CD is poorly understood, with some studies emphasizing the link between CD and the intestinal microbiota. Specifically, studies point to the brain-gut-enteric microbiota axis as a key player in the occurrence and development of CD. Furthermore, investigations have shown white-matter lesions and neurologic deficits in patients with IBD. Based on these findings, brain activity changes in CD patients have been detected by blood oxygenation level dependent functional magnetic resonance imaging (BOLD-fMRI). BOLD-fMRI signal analysis by detecting local increases in relative blood oxygenation that result from neurotransmitter activity and thus reflecting local neuronal firing rates. Therefore, biochemical concentrations or metabolites may change in corresponding brain regions of CD patients. To further study this phenomenon, brain changes of CD patients can be detected non-invasively, effectively and accurately by BOLD-fMRI combined with magnetic resonance spectroscopy (MRS). This approach can further shed light on the mechanisms of brain in the occurrence and development of the neurological CD. Overall, this paper serves to review the current status and prospects on fMRI and MRS for patients with CD base on the brain-gut-enteric microbiota axis.

**Key words:** Brain-gut-enteric microbiota axis; Crohn’s disease; Functional magnetic resonance imaging; Functional magnetic resonance spectroscopy; Gut microbiota; Inflammatory bowel disease; Metabolite; Spectroscopy

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tips:** The occurrence and development of Crohn’s disease (CD) have strong links to the brain-gut-enteric microbiota axis and is associated with psychological factors such as stress, anxiety and depression. In patients with inflammatory bowel disease, studies have revealed white-matter lesions and neurologic disorders. Brain activity and biochemical changes in brain regions can be detected accurately by blood oxygenation level dependent functional magnetic resonance imaging combined with magnetic resonance spectroscopy in patients with CD. This approach can further shed light on the mechanism of occurrence of neurologic CD.

Lv K, Fan YH, Xu L, Xu MS. Brain changes in patients with Crohn’s disease detected by functional magnetic resonance imaging and spectroscopy. *World J Gastroenterol* 2017; In press

**INTRODUCTION**

Crohn's disease (CD) is a chronic, non-specific granulomatous inflammatory disorder which can affect any part of the digestive tract. Most commonly, CD affects the small intestine. CD is a phenotype of inflammatory bowel disease (IBD). Geographically, CD is most prevalent in developed, western countries. However, recent epidemiologic studies definitely support a rapid increase in disease incidence in developing countries. Factors such as urbanization, improved sanitation, increased use of antibiotics and modern western diets have all been attributed to the rise of CD[1,2]. Therefore; it should be highly valued that the prevalence of CD will only increase in the near future.

To date, the pathogenesis of CD is not fully understood. The current dogma attributes CD to biological factors such as immune response, genetic susceptibility, intestinal dysbiosis as well as external, environmental factors[3]. Many studies have demonstrated that the onset and development of CD are closely related to the intestinal microbiome; which has a strong relationship with the brain-gut-enteric microbiota axis in particular. In recent years, the mechanism of brain-gut-enteric microbiota axis in CD patients has gained more attention by researchers. In particular, the advent of blood oxygenation level dependent functional magnetic resonance imaging (BOLD-fMRI) and hydrogen proton magnetic resonance spectroscopy (1H-MRS) has allowed non-invasive detection of brain activity and biochemical changes. Using fMRI, Agostini et al and Bao et al. was able to detect abnormal functional activity in the cerebral cortex for patients with CD. This paper therefore serves as a comprehensive review of the current status and prospects on MRS and fMRI for evaluation of patients with Crohn’s disease based on the brain-gut-enteric microbiota axis.

**ROLE OF MICROBIOTA IN ONSET AND DEVELOPMENT OF CD**

The microbiome refers to the microorganisms, genomes and the local environment in the human intestine[4]. A healthy gut microbiome is traditionally comprised of around 100 trillion species of microbes; most of which are bacteria[5]. Interruption of the symbiotic relationship between microbiota and the gastrointestinal (GI) tract is referred to as dysbiosis; which perturbs host functions and is a precursor to disorders, such as IBD[6,7]. As Prosberg *et al*[8] demonstrated through a systematic review, patients with active IBD had lower abundance of intestinal flora compared to patients in remission. Furthermore, the phenotypes of CD and ulcerative colitis (UC) are distinct. Therefore, the pathogenesis of IBD involves complex interactions between the immune system, the microbiome and environmental factors in genetically susceptible individuals. Specifically, an imbalance in intestinal microflora for genetically susceptible individuals can lead to abnormal immune responses within the gut and lead to damage in the intestinal mucosal barrier[9]. This imbalance plays a key role in the progression of CD inflammation. In a study conducted by Erickson *et al*[10] the ileum of CD patients was found to exhibit altered carbohydrate metabolism, bacterial-host interactions and the presence of human host-secreted enzymes. It is hypothesized that the aforementioned changes in intestinal function are directly induced by an imbalanced microbiota. This result further highlights potential targets for the treatment of IBD patients[11].

**MICROBIOTA AND ITS LINK TO THE BRAIN-GUT AXIS**

The bidirectional signaling between the gastrointestinal tract and the brain is vital for sustaining homeostasis and regulated at the neural level by both the central and enteric nervous systems. Hormonal and immunological regulations are also known to play a part. Studies[12,13] have indicated that bacteria such as commensal, probiotic, and pathogenic bacteria in the gastrointestinal tract can activate peripheral neural pathways and central nervous system (CNS) signaling pathways. This result is hardly surprising as the gut microbiome plays an important role in basic neuroregenerative processes such as the formation of the blood-brain barrier, myelination, neurogenesis, and microglia maturation. Therefore, neural pathways in the enteric, autonomic and limbic systems along with the intestinal microbiota, immunological and endocrine systems are all regulated by the enteric microbiome. Meanwhile, the enteric nervous system (ENS) is composed of small nerve cells, enteric ganglia, the nerve connectors between these ganglia and nerve fibers that supply effector tissues. Effector tissues include intestinal smooth muscle, mucosal epithelium, intrinsic vascular and gastroenteropancreatic endocrine cells[14]. This relationship between brain and enteric system involving the nervous system and microbiome is known as brain-gut-enteric microbiota axis (Figure 1). A malfunction in just one of these pathways can influence the progression of CD[15-17].

Evidently, the enteric microbiome strongly impacts brain-gut communication in the brain-gut-enteric microbiota axis. Not surprisingly, intestinal bacterial colonization plays a major role in the development and maturation of immune and endocrine systems, which are the key factors underlying CNS signaling[18]. Under control of the CNS, cells from the intrinsic layer of the lumen release chemokines into the intestinal lumen; which can lead to gastrointestinal motility, secrete and changes in the intestinal permeability. All these factors perturb the gastrointestinal bacterial environment[19,20].

Animal studies[21,22] have confirmed that behavioral disorders (such as stress) can change the composition of the intestinal flora. One proposed mechanism regards mucus and norepinephrine secretion by epithelial cells under stress, which results in gastrointestinal motility changes and specific strain growth. A large number of studies[23-27] have confirmed that the factors such as stress, anxiety and depression can affect the activity and recurrence of CD. Recent data suggests that gastrointestinal inflammation caused by stress may be induced on the dysfunction of hypothalamic-pituitary-adrenal (HPA) axis. This inflammation is known to alter the interaction between bacterial and mucosal mast cells through corticotrophin releasing factor (CRF).

Current research[28] has also confirmed intestinal microbiota can directly alter neural biochemistry and that dysbiosis may directly contribute to mental illnesses in patients with intestinal disorders. The study compared parameters of anxiety-like behavior and motor activity between specific pathogen free (SPF) mice with a normal gut microbiota and germ free (GF) mice. The GF mice exhibited decreased anxiety and increased motor activity. Further studies[29-31] also revealed that animals with non-invasive infections of pathogens in the cecum showed rapid activation of brainstem nuclei and exhibited anxiety like behavior. This reaction is believed to be mediated by signals from the vagal afferents to the nuclei of the solitary tract and the lateral parabrachial nuclei.

These studies have proved that the occurrence and development of CD has strong links to brain-gut-enteric microbiota axis and are involved with psychological factors such as stress, anxiety and depression.

**BOLD-fMRI IN BRAIN CHANGES OF CD**

BOLD-fMRI[32,33] was first reported by Ogawa et al in 1990 and has since become a powerful method for detecting brain activity. BOLD-fMRI functions by detecting local increases in relative blood oxygenation that result from neurotransmitter activity and thus reflect local neuronal firing rates (Figure 2). The activity of nervous system activity is therefore detected indirectly by assaying the proportion between deoxyhemoglobin and oxyhemoglobin in the blood. Inspection methods are divided into the task state and resting state (rs-fMRI). The task state is further subdivided into block design and event related methods.

The resting state is characterized by behaviors such as slow breathing and minimal physical or mental activity. In the absence of design tasks, subjects are known to cooperate willingly with high consistency. Replicative measures are therefore more easily obtained in large numbers in the resting state. During the resting state, Rs-fMRI detects low frequency fluctuations in functional brain regions based on blood oxygen level. Rs-fMRI analytical methods include regional homogeneity (ReHo)[34],functional connectivity (FC)[35] and amplitude of low-frequency fluctuation (ALFF)[36] *et al*. Using fMRI, Agostini et al and Bao et al. found abnormal functional activity in the cerebral cortex for patients with CD (Table 1).

Agostini *et al*[37] hypothesized inadequate habituation to stress as a characteristic for CD patients, and the study sought to compare neural habituation between CD patients and healthy subjects. During a high-stress task, different neural regions were activated between the two groups. Particular differences arose in the activation of the amygdala, hippocampus, insula, putamen and cerebellar regions. These contrasts revealed stark differences in the habituation to stress between CD affected individuals and controls. Particularly, CD patients demonstrated inadequate habituation to stress as previously hypothesized; which contribute a link between stress and exacerbated inflammation. These results suggested that the self-regulation of stress levels in CD patients is decreased, which can be an important factor in exacerbating intestinal inflammation.

Bao *et al*[38] investigated changes in resting-state brain activity in paracmastic CD patients with and without abdominal pain. Regional homogeneity (ReHo) was used to assess resting-state brain activity. They found that patients with abdominal pain exhibited lower ReHo values in the insula, middle cingulate cortex (MCC) and supplementary motor area (SMA), with higher ReHo values in the temporal pole. In contrast, patients without abdominal pain exhibited lower ReHo values in the hippocampal/parahippocampal cortex and higher ReHo values in the dorsomedial prefrontal cortex. These results showed a significant negative correlation between the ReHo values of the insular and MCC activities with the daily pain scores of patients with abdominal pain. The results of this study confirmed a difference in resting state brain activity between CD patients with and without abdominal pain. Furthermore, the abnormal activity of insular and MCC regions was closely related to the severity of abdominal pain.

**MRS AND METABOLOMICS IN CD**

MRS[39] utilize nuclear magnetic resonance phenomena and chemical shifts to quantitatively analyze of specific atomic nuclei and their compounds. As a non-invasive, quantitative measurement for physiological and biochemical changes of internal organs and tissue metabolism, MRS offers unparalleled versatility and safety. Not only does MRS characterize functional groups, but describes the relationships of appropriate nuclei different constitutional isomers and stereoisomers. To date, in vivo MRS of the brain in CD patients has yet to be implemented. Studies of MRS frequently use in *ex-vivo* samples of CD patients, such as serum/plasma, urine, stool and colonic mucosal samples (Table 1).

MRS proves useful in the study of metabolomics, which involves the high throughput analysis, characterization and quantification of small molecular metabolites. Assaying different fluids, such as serum/plasma, urine and stool samples, the presence or absence of different metabolites can be used to distinguish between IBD and healthy volunteers. MRS can even be used to discern the different subtypes (CD and UC) of IBD as metabolite changes are directly associated with changes in intestinal bacteria[40].These findings demonstrate that IBD is a disorder of the intestinal flora.

The differential diagnosis between CD and UC is often difficult. However, Bezabeh[41] utilized 1H-MRS combined with spectral data by multivariate to delineate UC and CD. Tissue samples from the colon of affected patients were assayed by spectral analysis, with a 98.6% accuracy rate for discerning UC and CD. The diagnostic spectral regions include taurine, lysine, and lipids.

In another using MRS for metabolomics, Varma *et al*[42] performed 1H-MRS on ex-vivo colonic mucosal samples for the early screening of IBD. Their results revealed differing levels of creatinine and phosphatidylcholine over time between IBD affected and healthy groups, and suggest the existence of biochemical changes in IBD.

Separately, Fathi *et al*[43] explored the biomarkers of metabolism in patients with CD and its correlation with serum zinc. Using 1H-MRS metabolic profiling of the serum samples, it was shown that valine and isoleucine levels are also useful in the differential diagnosis of CD metabolites, and these metabolites can be used for high risk screening for early diagnosis of CD patients.

**CLINICAL APPLICATIONS OF MRS AND FUTURE DIRECTIONS**

The most widely used clinical applications of MRS have been in the assessment of neurologic disorders. Previous studies[44,45] have shown that in vivo quantitative or semi-quantitative detection of brain tissue metabolites including glutamine (Glu), glutamate (Gln), γ-aminobutyric acid (GABA), N-acetylaspartate (NAA), myo-inositol (mI), choline (Cho), creatine (Cr), glycerophosphorylcholine (GPC) and phosphorylcholine (PC) can indicate neurological cell density, metabolism, permeability and other factors. The functions of clinically detectable neurochemical metabolites are listed in table 2. Therefore, in vivo MRS is instrumental in the diagnosis of brain diseases such as tumors, ischemia, infection, epilepsy, metabolic disorders, dementia, mental diseases, and so on[46,47]. MRS combined with clinical evaluations and conventional MRI is essential for diagnosing certain entities. Further studies[48,49] have shown that white-matter lesions and neurologic deficits in IBD patients may be an additional extra-intestinal manifestation of this disease. Despite the versatility of MRS however, current studies more frequently employ CD spectrum analysis of urine and fecal samples of CD patients. Meanwhile, *in vivo* MRS in the brain of CD patients has yet to be implemented.

Neurotransmitter mediated signal transduction plays an important role in the regulation of cerebral blood flow, which is mainly controlled by astrocytes[50]. BOLD-fMRI studies have confirmed changes in local cerebral blood oxygen concentrations in patients with CD. Based on these two observations[37,38], it is hypothesized that metabolites of functional brain areas will be changed accordingly in patients with CD. Specifically, the excitatory and inhibitory neurotransmitters associated with mental and psychological factors such as Glu and GABA[51,52], respectively, are thought to vary. The coordination between excitatory and inhibitory neurotransmitters is the basis of regulated neuronal activity, and is correlated with the amplitude of the BOLD-fMRI signal. GABA baseline levels were negatively correlated with BOLD-fMRI signals of brain activity. This result indicates the correlation between the BOLD-fMRI signals and GABA levels[53].

In addition, Glu and Gln serve as major excitatory neurotransmitters. Due to their similar molecular structures, the pair is often referred to as Glx. Studies of MRS in chronic pain[54-56] suggested that altered levels of Glx and GABA are present in patients with chronic pain, suggesting the role of neurotransmitters in pain management. Mullins *et al*[57] further used 1H-MRS to investigate changes of brain metabolites in patients scoring high on the self-assessed pain scale. Results indicated that the onset of pain can induce a dynamic increase in Glu concentration in the anterior cingulate cortex. It was also found that an increased Glu concentration was significantly related to the pain level of participants' subjective experience.

While increases in Glx are corresponded to increased pain perception, GABA[44,58,59] is an inhibitory neurotransmitter which plays an important role with Glx in neurotransmission and pain. GABA concentration in brain tissue in vivo is relatively low (< 2 mmol/l), and the MRS spectrum shows strong overlap with other metabolites. Therefore, traditional MRS is not optimal for detecting GABA. In light of this limitation, the spectral editing technique, MEGA-PRESS (MEscher-GArwood Point RESolved Spectroscopy)[60] was designed to allow accurate detection of GABA. Results are encouraging, and offer potential applications in the screening of neurodegenerative diseases, mental disorders, acute and chronic pain.

The use of functional magnetic resonance spectroscopy (fMRS) has been proposed for various applications[61-65], especially involved with psychological factors. MRS combined with fMRI is known as fMRS and can be used to detect changes in brain metabolites with high accuracy.

**CONCLUSION**

Current BOLD-fMRI studies have confirmed changes in local cerebral blood oxygen concentrations for patients with CD. Therefore, it is hypothesized that the level of metabolites in functional brain areas will be changed accordingly. The correlation of these changes can be related with the pathogenesis of CD. Meanwhile, the progression of CD with respect to psychological factors and symptom of abdominal pain in CD are requires further investigate. Based on brain-gut-enteric microbiota axis, fMRS can be used to study brain activity and biochemical concentrations of key neurotransmitters, particularly Glx and GABA, in patients with CD. fMRS studies therefore offer unpatrolled versatility for evaluation of patients with CD and serve to prevent further disease progression and relieve symptoms of abdominal pain for patients suffering from CD.

**REFERENCES**

1 **Molodecky NA**, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology* 2012; **142**: 46-54.e42; quiz e30 [PMID: 22001864 DOI: 10.1053/j.gastro.2011.10.001]

2 **Ng SC**, Bernstein CN, Vatn MH, Lakatos PL, Loftus EV, Tysk C, O'Morain C, Moum B, Colombel JF. Geographical variability and environmental risk factors in inflammatory bowel disease. *Gut* 2013; **62**: 630-649 [PMID: 23335431 DOI: 10.1136/gutjnl-2012-303661]

3 **Sartor RB**. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. *Nat Clin Pract Gastroenterol Hepatol* 2006; **3**: 390-407 [PMID: 16819502 DOI: 10.1038/ncpgasthep0528]

4 **Gill SR**, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, Gordon JI, Relman DA, Fraser-Liggett CM, Nelson KE. Metagenomic analysis of the human distal gut microbiome. *Science* 2006; **312**: 1355-1359 [PMID: 16741115 DOI: 10.1126/science.1124234]

5 **Qin J**, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 2010; **464**: 59-65 [PMID: 20203603 DOI: 10.1038/nature08821]

6 **Collins SM**, Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. *Gastroenterology* 2009; **136**: 2003-2014 [PMID: 19457424 DOI: 10.1053/j.gastro.2009.01.075]

7 **Lepage P**, Colombet J, Marteau P, Sime-Ngando T, Doré J, Leclerc M. Dysbiosis in inflammatory bowel disease: a role for bacteriophages? *Gut* 2008; **57**: 424-425 [PMID: 18268057 DOI: 10.1136/gut.2007.134668]

8 **Prosberg M**, Bendtsen F, Vind I, Petersen AM, Gluud LL. The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis. *Scand J Gastroenterol* 2016; **51**: 1407-1415 [PMID: 27687331 DOI: 10.1080/00365521.2016.1216587]

9 **Boyapati R**, Satsangi J, Ho GT. Pathogenesis of Crohn's disease. *F1000Prime Rep* 2015; **7**: 44 [PMID: 26097717 DOI: 10.12703/P7-44]

10 **Erickson AR**, Cantarel BL, Lamendella R, Darzi Y, Mongodin EF, Pan C, Shah M, Halfvarson J, Tysk C, Henrissat B, Raes J, Verberkmoes NC, Fraser CM, Hettich RL, Jansson JK. Integrated metagenomics/metaproteomics reveals human host-microbiota signatures of Crohn's disease. *PLoS One* 2012; **7**: e49138 [PMID: 23209564 DOI: 10.1371/journal.pone.0049138]

11 **Hold GL**, Smith M, Grange C, Watt ER, El-Omar EM, Mukhopadhya I. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? *World J Gastroenterol* 2014; **20**: 1192-1210 [PMID: 24574795 DOI: 10.3748/wjg.v20.i5.1192]

12 **Foster JA**, Neufeld MV. Gut-brain axis: how the microbiome influences anxiety and depression: Trends in Neurosciences. *Trends Neurosci* 2013; **36**:305-312 [PMID: 23384445 DOI: 10.1016/j.tins.2013.01.005]

13 **Sharon G**, Sampson TR, Geschwind DH, Mazmanian SK. The Central Nervous System and the Gut Microbiome. *Cell* 2016; **167**: 915-932 [PMID: 27814521 DOI: 10.1016/j.cell.2016.10.027]

14 **Furness JB**. The enteric nervous system and neurogastroenterology. *Nat Rev Gastroenterol Hepatol* 2012; **9**: 286-294 [PMID: 22392290 DOI: 10.1038/nrgastro.2012.32]

15 **Cryan JF**, O'Mahony SM. The microbiome-gut-brain axis: from bowel to behavior. *Neurogastroenterol Motil* 2011; **23**: 187-192 [PMID: 21303428 DOI: 10.1111/j.1365-2982.2010.01664.x]

16 **Bonaz BL**, Bernstein CN. Brain-gut interactions in inflammatory bowel disease. *Gastroenterology* 2013; **144**: 36-49 [PMID: 23063970 DOI: 10.1053/j.gastro.2012.10.003]

17 **Collins SM**, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. *Nat Rev Microbiol* 2012; **10**: 735-742 [PMID: 23000955 DOI: 10.1038/nrmicro2876]

18 **Grenham S**, Clarke G, Cryan JF, Dinan TG. Brain-gut-microbe communication in health and disease. *Front Physiol* 2011; **2**: 94 [PMID: 22162969 DOI: 10.3389/fphys.2011.00094]

19 **Rhee SH**, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. *Nat Rev Gastroenterol Hepatol* 2009; **6**: 306-314 [PMID: 19404271 DOI: 10.1038/nrgastro.2009.35]

20 **Mayer EA**. The neurobiology of stress and gastrointestinal disease. *Gut* 2000; **47**: 861-869 [PMID: 11076888]

21 **Chen C**, Brown DR, Xie Y, Green BT, Lyte M. Catecholamines modulate Escherichia coli O157: H7 adherence to murine cecal mucosa. *Shock* 2003; **20**: 183-188 [PMID: 12865665 DOI: 10.1097/01.shk.0000073867.66587.e0]

22 **O'Mahony SM**, Marchesi JR, Scully P, Codling C, Ceolho AM, Quigley EM, Cryan JF, Dinan TG. Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses. *Biol Psychiatry* 2009; **65**: 263-267 [PMID: 18723164 DOI: 10.1016/j.biopsych.2008.06.026]

23 **Ananthakrishnan AN**, Khalili H, Pan A, Higuchi LM, de Silva P, Richter JM, Fuchs CS, Chan AT. Association between depressive symptoms and incidence of Crohn's disease and ulcerative colitis: results from the Nurses' Health Study. *Clin Gastroenterol Hepatol* 2013; **11**: 57-62 [PMID: 22944733 DOI: 10.1016/j.cgh.2012.08.032]

24 **Cámara RJ**, Schoepfer AM, Pittet V, Begré S, von Känel R. Mood and nonmood components of perceived stress and exacerbation of Crohn's disease. *Inflamm Bowel Dis* 2011; **17**: 2358-2365 [PMID: 21287671 DOI: 10.1002/ibd.21623]

25 **Graff LA**, Walker JR, Bernstein CN. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. *Inflamm Bowel Dis* 2009; **15**: 1105-1118 [PMID: 19161177 DOI: 10.1002/ibd.20873]

26 **Mardini HE**, Kip KE, Wilson JW. Crohn's disease: a two-year prospective study of the association between psychological distress and disease activity. *Dig Dis Sci* 2004; **49**: 492-497 [PMID: 15139504]

27 **Mawdsley JE**, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. *Gut* 2005; **54**: 1481-1491 [PMID: 16162953 DOI: 10.1136/gut.2005.064261]

28 **Diaz Heijtz R**, Wang S, Anuar F, Qian Y, Björkholm B, Samuelsson A, Hibberd ML, Forssberg H, Pettersson S. Normal gut microbiota modulates brain development and behavior. *Proc Natl Acad Sci USA* 2011; **108**: 3047-3052 [PMID: 21282636 DOI: 10.1073/pnas.1010529108]

29 **Wang X**, Wang BR, Zhang XJ, Xu Z, Ding YQ, Ju G. Evidences for vagus nerve in maintenance of immune balance and transmission of immune information from gut to brain in STM-infected rats. *World J Gastroenterol* 2002; **8**: 540-545 [PMID: 12046088 doi: 10.3748/wjg.v8.i3.540]

30 **Goehler LE**, Lyte M, Gaykema RP. Infection-induced viscerosensory signals from the gut enhance anxiety: implications for psychoneuroimmunology. *Brain Behav Immun* 2007; **21**: 721-726 [PMID: 17428636 DOI: 10.1016/j.bbi.2007.02.005]

31 **Gaykema RP**, Goehler LE, Lyte M. Brain response to cecal infection with Campylobacter jejuni: analysis with Fos immunohistochemistry. *Brain Behav Immun* 2004; **18**: 238-245 [PMID: 15050651 DOI: 10.1016/j.bbi.2003.08.002]

32 **Matthews PM**, Jezzard P. Functional magnetic resonance imaging. *J Neurol Neurosurg Psychiatry* 2004; **75**: 6-12 [PMID: 14707297]

33 **Ogawa S**, Lee TM, Nayak AS, Glynn P. Oxygenation-sensitive contrast in magnetic resonance image of rodent brain at high magnetic fields. *Magn Reson Med* 1990; **14**: 68-78 [PMID: 2161986]

34 **Zang Y**, Jiang T, Lu Y, He Y, Tian L. Regional homogeneity approach to fMRI data analysis. *Neuroimage* 2004; **22**: 394-400 [PMID: 15110032 DOI: 10.1016/j.neuroimage.2003.12.030]

35 **Roy AK**, Shehzad Z, Margulies DS, Kelly AM, Uddin LQ, Gotimer K, Biswal BB, Castellanos FX, Milham MP. Functional connectivity of the human amygdala using resting state fMRI. *Neuroimage* 2009; **45**: 614-626 [PMID: 19110061 DOI: 10.1016/j.neuroimage.2008.11.030]

36 **Zou QH**, Zhu CZ, Yang Y, Zuo XN, Long XY, Cao QJ, Wang YF, Zang YF. An improved approach to detection of amplitude of low-frequency fluctuation (ALFF) for resting-state fMRI: fractional ALFF. *J Neurosci Methods* 2008; **172**: 137-141 [PMID: 18501969 DOI: 10.1016/j.jneumeth.2008.04.012]

37 **Agostini A**, Filippini N, Benuzzi F, Bertani A, Scarcelli A, Leoni C, Farinelli V, Riso D, Tambasco R, Calabrese C, Rizzello F, Gionchetti P, Ercolani M, Nichelli P, Campieri M. Functional magnetic resonance imaging study reveals differences in the habituation to psychological stress in patients with Crohn's disease versus healthy controls. *J Behav Med* 2013; **36**: 477-487 [PMID: 22752251 DOI: 10.1007/s10865-012-9441-1]

38 **Bao CH**, Liu P, Liu HR, Wu LY, Jin XM, Wang SY, Shi Y, Zhang JY, Zeng XQ, Ma LL, Qin W, Zhao JM, Calhoun VD, Tian J, Wu HG. Differences in regional homogeneity between patients with Crohn's disease with and without abdominal pain revealed by resting-state functional magnetic resonance imaging. *Pain* 2016; **157**: 1037-1044 [PMID: 26761381 DOI: 10.1097/j.pain.0000000000000479]

39 **Jackman LM**, Sternhell S. Application of Nuclear Magnetic Resonance Spectroscopy in Organic Chemistry: International Series in Organic Chemistry. Elsevier, 2013

40 **De Preter V**. Metabolomics in the Clinical Diagnosis of Inflammatory Bowel Disease. *Dig Dis* 2015; **33 Suppl 1**: 2-10

41 **Bezabeh T**, Somorjai RL, Smith IC, Nikulin AE, Dolenko B, Bernstein CN. The use of 1H magnetic resonance spectroscopy in inflammatory bowel diseases: distinguishing ulcerative colitis from Crohn's disease. *Am J Gastroenterol* 2001; **96**: 442-448 [PMID: 11232688 DOI: 10.1111/j.1572-0241.2001.03523.x]

42 **Varma S**, Bird R, Eskin M, Dolenko B, Raju J, Bezabeh T. Detection of inflammatory bowel disease by proton magnetic resonance spectroscopy (1H MRS) using an animal model. *J Inflamm (Lond)* 2007; **4**: 24 [PMID: 18039383 DOI: 10.1186/1476-9255-4-24]

43 **Fathi F**, Majari-Kasmaee L, Mani-Varnosfaderani A, Kyani A, Rostami-Nejad M, Sohrabzadeh K, Naderi N, Zali MR, Rezaei-Tavirani M, Tafazzoli M, Arefi-Oskouie A. 1H NMR based metabolic profiling in Crohn's disease by random forest methodology. *Magn Reson Chem* 2014; **52**: 370-376 [PMID: 24757065 DOI: 10.1002/mrc.4074]

44 **Foerster BR**, Pomper MG, Callaghan BC, Petrou M, Edden RA, Mohamed MA, Welsh RC, Carlos RC, Barker PB, Feldman EL. An imbalance between excitatory and inhibitory neurotransmitters in amyotrophic lateral sclerosis revealed by use of 3-T proton magnetic resonance spectroscopy. *JAMA Neurol* 2013; **70**: 1009-1016 [PMID: 23797905 DOI: 10.1001/jamaneurol.2013.234]

45 **Xu M**, Ye J, Yang D, Xu X, Yeo TT, Ng WH, Lim CC. Ex-vivo NMR of unprocessed tissue in water: a simplified procedure for studying intracranial neoplasms. *Anal Bioanal Chem* 2007; **389**: 2153-2159 [PMID: 17994295 DOI: 10.1007/s00216-007-1629-9]

46 **Oz G**, Alger JR, Barker PB, Bartha R, Bizzi A, Boesch C, Bolan PJ, Brindle KM, Cudalbu C, Dinçer A, Dydak U, Emir UE, Frahm J, González RG, Gruber S, Gruetter R, Gupta RK, Heerschap A, Henning A, Hetherington HP, Howe FA, Hüppi PS, Hurd RE, Kantarci K, Klomp DW, Kreis R, Kruiskamp MJ, Leach MO, Lin AP, Luijten PR, Marjańska M, Maudsley AA, Meyerhoff DJ, Mountford CE, Nelson SJ, Pamir MN, Pan JW, Peet AC, Poptani H, Posse S, Pouwels PJ, Ratai EM, Ross BD, Scheenen TW, Schuster C, Smith IC, Soher BJ, Tkáč I, Vigneron DB, Kauppinen RA. Clinical proton MR spectroscopy in central nervous system disorders. *Radiology* 2014; **270**: 658-679 [PMID: 24568703 DOI: 10.1148/radiol.13130531]

47 **Xu M**, See SJ, Ng WH, Arul E, Back MF, Yeo TT, Lim CC. Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. *Neurosurgery* 2005; **56**: 919-26; discussion 919-26 [PMID: 15854239]

48 **Geissler A**, Andus T, Roth M, Kullmann F, Caesar I, Held P, Gross V, Feuerbach S, Schölmerich J. Focal white-matter lesions in brain of patients with inflammatory bowel disease. *Lancet* 1995; **345**: 897-898 [PMID: 7707814]

49 **Morís G**. Inflammatory bowel disease: an increased risk factor for neurologic complications. *World J Gastroenterol* 2014; **20**: 1228-1237 [PMID: 24574797 DOI: 10.3748/wjg.v20.i5.1228]

50 **Attwell D**, Buchan AM, Charpak S, Lauritzen M, Macvicar BA, Newman EA. Glial and neuronal control of brain blood flow. *Nature* 2010; **468**: 232-243 [PMID: 21068832 DOI: 10.1038/nature09613]

51 **Schür RR**, Draisma LW, Wijnen JP, Boks MP, Koevoets MG, Joëls M, Klomp DW, Kahn RS, Vinkers CH. Brain GABA levels across psychiatric disorders: A systematic literature review and meta-analysis of (1) H-MRS studies. *Hum Brain Mapp* 2016; **37**: 3337-3352 [PMID: 27145016 DOI: 10.1002/hbm.23244]

52 **Yüksel C**, Öngür D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. *Biol Psychiatry* 2010; **68**: 785-794 [PMID: 20728076 DOI: 10.1016/j.biopsych.2010.06.016]

53 **Donahue MJ**, Near J, Blicher JU, Jezzard P. Baseline GABA concentration and fMRI response. *Neuroimage* 2010; **53**: 392-398 [PMID: 20633664 DOI: 10.1016/j.neuroimage.2010.07.017]

54 **Hansen TM**, Olesen AE, Simonsen CW, Drewes AM, Frøkjær JB. Cingulate metabolites during pain and morphine treatment as assessed by magnetic resonance spectroscopy. *J Pain Res* 2014; **7**: 269-276 [PMID: 24899823 DOI: 10.2147/JPR.S61193]

55 **Harris RE**, Clauw DJ. Imaging central neurochemical alterations in chronic pain with proton magnetic resonance spectroscopy. *Neurosci Lett* 2012; **520**: 192-196 [PMID: 22445845 DOI: 10.1016/j.neulet.2012.03.042]

56 **Watson CJ**. Insular balance of glutamatergic and GABAergic signaling modulates pain processing. *Pain* 2016; **157**: 2194-2207 [PMID: 27218870 DOI: 10.1097/j.pain.0000000000000615]

57 **Mullins PG**, Rowland LM, Jung RE, Sibbitt WL. A novel technique to study the brain's response to pain: proton magnetic resonance spectroscopy. *Neuroimage* 2005; **26**: 642-646 [PMID: 15907322 DOI: 10.1016/j.neuroimage.2005.02.001]

58 **Aguila ME**, Lagopoulos J, Leaver AM, Rebbeck T, Hübscher M, Brennan PC, Refshauge KM. Elevated levels of GABA+ in migraine detected using (1) H-MRS. *NMR Biomed* 2015; **28**: 890-897 [PMID: 25997981 DOI: 10.1002/nbm.3321]

59 **Cleve M**, Gussew A, Reichenbach JR. In vivo detection of acute pain-induced changes of GABA+ and Glx in the human brain by using functional 1H MEGA-PRESS MR spectroscopy. *Neuroimage* 2015; **105**: 67-75 [PMID: 25462698 DOI: 10.1016/j.neuroimage.2014.10.042]

60 **Mescher M**, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneous in vivo spectral editing and water suppression. *NMR Biomed* 1998; **11**: 266-272 [PMID: 9802468]

61 **Apšvalka D**, Gadie A, Clemence M, Mullins PG. Event-related dynamics of glutamate and BOLD effects measured using functional magnetic resonance spectroscopy (fMRS) at 3T in a repetition suppression paradigm. *Neuroimage* 2015; **118**: 292-300 [PMID: 26072254 DOI: 10.1016/j.neuroimage.2015.06.015]

62 **Jahng GH**, Oh J, Lee DW, Kim HG, Rhee HY, Shin W, Paik JW, Lee KM, Park S, Choe BY, Ryu CW. Glutamine and Glutamate Complex, as Measured by Functional Magnetic Resonance Spectroscopy, Alters During Face-Name Association Task in Patients with Mild Cognitive Impairment and Alzheimer's Disease. *J Alzheimers Dis* 2016; **52**: 145-159 [PMID: 27060946 DOI: 10.3233/JAD-150877]

63 **Huang Z**, Davis HH, Yue Q, Wiebking C, Duncan NW, Zhang J, Wagner NF, Wolff A, Northoff G. Increase in glutamate/glutamine concentration in the medial prefrontal cortex during mental imagery: A combined functional mrs and fMRI study. *Hum Brain Mapp* 2015; **36**: 3204-3212 [PMID: 26059006 DOI: 10.1002/hbm.22841]

64 **Taylor R**, Neufeld RW, Schaefer B, Densmore M, Rajakumar N, Osuch EA, Williamson PC, Théberge J. Functional magnetic resonance spectroscopy of glutamate in schizophrenia and major depressive disorder: anterior cingulate activity during a color-word Stroop task. *NPJ Schizophr* 2015; **1**: 15028 [PMID: 27336037 DOI: 10.1038/npjschz.2015.28]

65 **Bednařík P**, Tkáč I, Giove F, DiNuzzo M, Deelchand DK, Emir UE, Eberly LE, Mangia S. Neurochemical and BOLD responses during neuronal activation measured in the human visual cortex at 7 Tesla. *J Cereb Blood Flow Metab* 2015; **35**: 601-610 [PMID: 25564236 DOI: 10.1038/jcbfm.2014.233]

66 **Govindaraju V**, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. *NMR Biomed* 2000; **13**: 129-153 [PMID: 10861994]

**P-Reviewer:** Lakatos PL, Ozen H, Tantau A **S-Editor:** Gong ZM

**L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

****

**Figure 1 Brain-gut-enteric microbiota axis.** The bidirectional brain-gut-enteric microbiota axis between brain and gut involved with neural pathways, immunological and endocrine mechanisms; which is closely associated with microbiota and psychological disorders such as depression, anxiety and stress. These disorders may result in FGID, IBD and IBS. FGID: functional gastrointestinal disorders; IBD: inflammatory bowel disease; IBS: irritable bowel syndrome.

****

**Figure 2 Mechanism of blood oxygenation level dependent functional magnetic resonance imaging.** BOLD-fMRI signal analysis by detecting local increases in relative blood oxygenation resulting from neurotransmitter activity and reflecting local neuronal firing rates. The activity of nervous system activity is detected indirectly by assaying the proportion between deoxyhemoglobin and oxyhemoglobin in the blood. BOLD-fmri: blood oxygenation level dependent functional magnetic resonance imaging.

**Table 1 Studies of blood oxygenation level dependent functional magnetic resonance imaging and magnetic resonance spectroscopy in Crohn's disease**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Study | Destination | Inspection | Location | Main metabolites | Results |
| Agostini *et al*[37], 2013 | Habituation to stress in CD | BOLD-fMRI (Task-state) | Brain | NA | Different neural activity in amygdala, hippocampus, insula, putamen and cerebellar between CD patients and controls. |
| Bao *et al*[38], 2016 | Brain activity in paracmastic CD patients | BOLD-fMRI (Resting-state) | Brain | NA | ReHo values: Abdominal pain: insula, MCC, SMA↑, temporal pole↓; Without abdominal pain: hoppocampal/parahippocampial cortex↑, dorsomedial prefrontal cortex↓ |
| Bezabeh *et al*[41], 2001 | Diagnosis in CD and UC | MRS | Colonic mucosal | Taurine, lysine, lipid, choline, creatine | The diagnostic spectral regions include taurine, lysine, and lipids. |
| Varma *et al*[42], 2007 | Early screening of IBD | MRS | Colonic mucosal | Creatinine and phosphatidylcholine | Triglycerides, creatine, phosphocholine and glycerol backbone of lipids are the most discriminatory metabolites |
| Fathi *et al*[43], 2014 | Biomarkers of CD | MRS | Serum | Alanine, glutamine, leucine/isoleucine, lysine and valine | Two chemical shifts of isoleucine (0.99 ppm) and valine (1.03 ppm) have considerable impact for discriminating patient and normal samples. |

BOLD-fMRI: blood oxygenation level dependent functional magnetic resonance imaging; CD: Crohn's disease; IBD: inflammatory bowel disease; MCC: middle cingulate cortex; MRS: magnetic resonance spectroscopy; NA: not available; ReHo: regional homogeneity; SMA: supplementary motor area; UC: Ulcerative colitis.

**Table 2 Metabolites of magnetic resonance spectroscopy and functions in normal adult human brain[66]**

|  |  |  |  |
| --- | --- | --- | --- |
| Metabolites | Chemical shifts (ppm) | Concentration range (mmol/kgww) | Functions |
| NAA | 2.02 | 7.9-16.6 (average 10.3) | An osmolite, a storage form of aspartate, a precursor of NAAG, a marker of neuronal density |
| GABA | 3.01 | 1.3-1.9 | A primary inhibitory neurotransmitter |
| tCho | 3.20 | 0.9-2.5 | An essential nutrient that required for synthesis of the neurotransmitter acetylcholine, and of phosphatidylcholine, a major constituent of membranes |
| Cr | 3.05 | 5.1-10.6 | A concentration reference |
| Glu  | 2.04-2.35 | 6.0-12.5 | An excitatory neurotransmitter |
| Gln | 2.12-2.46 | 3.0-5.8 | A precursor and storage form of glutamate |
| mI | 3.56 | 3.8-8.1 | An essential requirement for cell growth, and a storage form for glucose |
| Lac | 1.33-1.35 | 0.4 | The end product of anaerobic glycolysis |

Cr: creatine; GABA: γ-aminobutyric acid; Glu: glutamate; Gln: glutamine; Lac: Lactate; mI, myo-inositol; mmol/kgww: mmol/kg of wet weight; NAA: N-acetylaspartate; ppm, parts per million; tCho: Choline (total), free choline, glycerophosphorylcholine, and phosphorylcholine.